Logo for G1 Therapeutics Inc

G1 Therapeutics Investor Relations Material

Latest events

Logo for G1 Therapeutics Inc

Q4 2023

G1 Therapeutics
Logo for G1 Therapeutics

Q4 2023

28 Feb, 2024
Logo for G1 Therapeutics

Corporate Presentation

15 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from G1 Therapeutics Inc

Access all reports
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's lead product candidate is trilaciclib (G1T48), which is in Phase 3 clinical trial for use as a chemoprotective agent to mitigate the cardiopulmonary toxicity associated with chemotherapy comprising anthracycline and cyclophosphamide administered in the adjuvant, locally advanced or metastatic setting; and that is in Phase 1b/2 trial for use with carboplatin.